Tizona Therapeutics Stock

tizonatx.comHealthcareFounded: 2015Funding to Date: $95.24MM

Tizona Therapeutics is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases.

Register for Details

For more details on financing and valuation for Tizona Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Tizona Therapeutics.

Register Today

Team

Management Team

Scott Clarke
Chief Executive Officer & Board Member
Mark Smyth Ph.D
Advisor Board Member & Scientific Co-Founder
Christine O'Brien
Chief Operating Officer
Shelly Pinto
Controller & Vice President, Finance
Joyson Karakunnel MD
Chief Medical Officer & Senior Vice President
Courtney Beers Ph.D
Chief Scientific Officer
John Corbin Ph.D
Chief Technology Officer

Board Members

Daniel Spiegelman
Scott Clarke
Daniel Hicklin Ph.D
MPM Capital
Nina Kjellson
Canaan Partners
Shelley Chu Ph.D
Abingworth Management
Luke Evnin Ph.D
MPM Capital
Pablo Cagnoni MD
MPM Capital

Other companies like Tizona Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 

News

A cancer immunotherapy teed up for clinical trials by Tizona Therapeutics is now the centerpiece of a new partnership with AbbVie, which is paying the
Tizona Therapeutics Inc, a company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases, raised $43 million in Series B funding. Abingworth and Canaan Partners led the round with participation from Lightstone Ventures and existing Series A investors, including MPM Capital, Amgen Ventures, Astellas Venture Management and InterWest Partners.